Eyepoint Financial Statements From 2010 to 2024
| EYPT Stock | USD 16.47 1.10 6.26% |
Gross Profit 26.9 M | Profit Margin (1.54) | Market Capitalization 875.5 M | Enterprise Value Revenue 17.2336 | Revenue 46 M |
Eyepoint Pharmaceuticals Total Revenue |
|
Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint main balance sheet or income statement drivers, such as Depreciation And Amortization of 440.8 K, Interest Expense of 1.6 M or Total Revenue of 48.3 M, as well as many exotic indicators such as Price To Sales Ratio of 18.09, Dividend Yield of 0.0 or PTB Ratio of 3.13. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.
Eyepoint | Select Account or Indicator |
Eyepoint Pharmaceuticals Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eyepoint Pharmaceuticals Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eyepoint Pharmaceuticals Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eyepoint Pharmaceuticals Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eyepoint Fundamental Market Drivers
| Cash And Short Term Investments | 331.1 M |
Eyepoint Upcoming Events
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About Eyepoint Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Eyepoint Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Eyepoint Pharmaceuticals investors use historical funamental indicators, such as Eyepoint Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Eyepoint Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eyepoint Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eyepoint Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eyepoint Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 38.6 M | 40.5 M | |
| Total Revenue | 46 M | 48.3 M | |
| Cost Of Revenue | 4.6 M | 4.4 M | |
| Stock Based Compensation To Revenue | 0.26 | 0.46 | |
| Sales General And Administrative To Revenue | 0.87 | 0.83 | |
| Research And Ddevelopement To Revenue | 1.40 | 1.33 | |
| Capex To Revenue | (0.08) | (0.08) | |
| Revenue Per Share | 1.18 | 1.94 | |
| Ebit Per Revenue | (1.60) | (1.68) |
Pair Trading with Eyepoint Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyepoint Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyepoint Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eyepoint Stock
| 0.68 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.65 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
| 0.63 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.61 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.53 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
The ability to find closely correlated positions to Eyepoint Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyepoint Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyepoint Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyepoint Pharmaceuticals to buy it.
The correlation of Eyepoint Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyepoint Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyepoint Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyepoint Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Eyepoint Pharmaceuticals Correlation against competitors. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Eyepoint Stock analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Eyepoint Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyepoint Pharmaceuticals. If investors know Eyepoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyepoint Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 1.183 | Quarterly Revenue Growth 0.332 | Return On Assets (0.17) | Return On Equity (0.39) |
The market value of Eyepoint Pharmaceuticals is measured differently than its book value, which is the value of Eyepoint that is recorded on the company's balance sheet. Investors also form their own opinion of Eyepoint Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eyepoint Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyepoint Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eyepoint Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyepoint Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyepoint Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyepoint Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.